XCL1 and neoplasm: The loss of Flt3L, CCL5, and XCL1 secretion by tumor-infiltrating NK cells impacts recruitment and survival of cross-presenting DCs, and correlates with increased tumor growth [22,24,25,26] and responsiveness to anti-PD1 therapy [25].